Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Analysis of Profitability Ratios

Microsoft Excel

Profitability Ratios (Summary)

Allergan Inc., profitability ratios

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Return on Sales
Gross profit margin 86.60% 85.28% 84.12% 83.61% 82.16%
Operating profit margin 28.20% 29.19% 28.26% 25.53% 5.37%
Net profit margin 21.39% 15.90% 19.25% 17.48% 0.01%
Return on Investment
Return on equity (ROE) 19.66% 15.24% 18.82% 17.60% 0.01%
Return on assets (ROA) 12.28% 9.32% 11.97% 10.98% 0.01%

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Allergan Inc. gross profit margin ratio improved from 2012 to 2013 and from 2013 to 2014.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Allergan Inc. operating profit margin ratio improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Allergan Inc. net profit margin ratio deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Allergan Inc. ROE deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level.
ROA A profitability ratio calculated as net income divided by total assets. Allergan Inc. ROA deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level.

Gross Profit Margin

Allergan Inc., gross profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Selected Financial Data (US$ in thousands)
Gross profit 6,171,300 5,285,000 4,802,000 4,470,800 3,959,600
Product net sales 7,126,100 6,197,500 5,708,800 5,347,100 4,819,600
Profitability Ratio
Gross profit margin1 86.60% 85.28% 84.12% 83.61% 82.16%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

1 2014 Calculation
Gross profit margin = 100 × Gross profit ÷ Product net sales
= 100 × 6,171,300 ÷ 7,126,100 = 86.60%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Allergan Inc. gross profit margin ratio improved from 2012 to 2013 and from 2013 to 2014.

Operating Profit Margin

Allergan Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Selected Financial Data (US$ in thousands)
Operating income 2,009,300 1,809,300 1,613,300 1,365,100 258,600
Product net sales 7,126,100 6,197,500 5,708,800 5,347,100 4,819,600
Profitability Ratio
Operating profit margin1 28.20% 29.19% 28.26% 25.53% 5.37%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

1 2014 Calculation
Operating profit margin = 100 × Operating income ÷ Product net sales
= 100 × 2,009,300 ÷ 7,126,100 = 28.20%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Allergan Inc. operating profit margin ratio improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014.

Net Profit Margin

Allergan Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Selected Financial Data (US$ in thousands)
Net earnings attributable to Allergan, Inc. 1,524,200 985,100 1,098,800 934,500 600
Product net sales 7,126,100 6,197,500 5,708,800 5,347,100 4,819,600
Profitability Ratio
Net profit margin1 21.39% 15.90% 19.25% 17.48% 0.01%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

1 2014 Calculation
Net profit margin = 100 × Net earnings attributable to Allergan, Inc. ÷ Product net sales
= 100 × 1,524,200 ÷ 7,126,100 = 21.39%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Allergan Inc. net profit margin ratio deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level.

Return on Equity (ROE)

Allergan Inc., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Selected Financial Data (US$ in thousands)
Net earnings attributable to Allergan, Inc. 1,524,200 985,100 1,098,800 934,500 600
Total Allergan, Inc. stockholders’ equity 7,753,000 6,463,200 5,837,100 5,309,600 4,757,700
Profitability Ratio
ROE1 19.66% 15.24% 18.82% 17.60% 0.01%
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

1 2014 Calculation
ROE = 100 × Net earnings attributable to Allergan, Inc. ÷ Total Allergan, Inc. stockholders’ equity
= 100 × 1,524,200 ÷ 7,753,000 = 19.66%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Allergan Inc. ROE deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level.

Return on Assets (ROA)

Allergan Inc., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Selected Financial Data (US$ in thousands)
Net earnings attributable to Allergan, Inc. 1,524,200 985,100 1,098,800 934,500 600
Total assets 12,415,700 10,574,300 9,179,300 8,508,600 8,308,100
Profitability Ratio
ROA1 12.28% 9.32% 11.97% 10.98% 0.01%
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

1 2014 Calculation
ROA = 100 × Net earnings attributable to Allergan, Inc. ÷ Total assets
= 100 × 1,524,200 ÷ 12,415,700 = 12.28%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Allergan Inc. ROA deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level.